tirzepatide 1.5 mg GLP-1/GIP Rx Tirzepatide | 5mg

doi: 10.1093/carcin/bgv120 [DOI] [PubMed] [Google Scholar] 295

On average, patients who took tirzepatide lost between 18% and 20% of their body weight and showed improvements in blood pressure and a condition where blood oxygen levels drop during sleep

Certain variants predict higher weight regain risk after stopping therapy, helping you and your provider decide whether long-term maintenance or indefinite treatment aligns with your biology and health goals

Author contributions B

A systematic review of 9,871 participants found a relative risk of 1.97 for composite gallbladder and biliary disease

Patients whose genetic profile suggests strong GLP-1 sensitivity may reach therapeutic effects at lower doses, minimizing digestive side effects